Eisai

Eisai’s Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India

Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris Tokyo, September 21, 2019: …

5 years ago

Eisai to Present Latest Data on Lemborexant at World Sleep Congress

Tokyo September 21, 2019: Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being…

5 years ago

Eisai Receives Iia Japan Chairman’s Award of Institute of Internal Auditors – Japan

New Delhi, September 19, 2019: Eisai Co., Ltd. has announced that it received the 33rd "IIA Japan Chairman's Award" of…

5 years ago

Eisai to Launch New “Etak Antimicrobial Wet Wipes” With One Week Lasting Antimicrobial Action

Alcohol-Free Wipe for Eliminating Viruses and Bacteria on Personal Belongings Tokyo, August 29, 2019: Eisai Co., Ltd. will launch ETAK(…

5 years ago

Eisai Enters Into Business Alliance With Cogstate for Exclusive Development and Commercialization of a Digital Tool for Self-Assessment of Cognitive Function in Japan

Tokyo, August 29, 2019: Eisai Co., Ltd. has entered into a business alliance agreement for exclusive development and commercialization of…

5 years ago

Eisai Presented Latest Trends of Treatment for Alzheimer’s at AAIC 2019

New Delhi, July 25, 2019: Eisai Co.,Ltd. announced the presentation and discussion about the treatment, including oral beta amyloid cleaving…

5 years ago

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA

For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not…

5 years ago

Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019

Without Significant Effects on Synaptic Function in Brain by Spinal Densitiy Evaluation at Effective Dose to Decrease Amyloid Beta Level…

5 years ago

Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019

Tokyo, July 18, 2019: Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma…

5 years ago

Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting

Tokyo, May 16, 2019: Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its…

5 years ago